Human neutrophil formyl peptide receptor phosphorylation and the mucosal inflammatory response.
Bacterial/mitochondrial fMLF analogs bind FPR1, driving accumulation/activation of PMN at sites of infection/injury, while promoting wound healing in epithelia. We quantified levels of UFPR1 and TFPR1 in isolated PMN by use of phosphosensitive NFPRb and phosphorylation-independent NFPRa antibodies. UFPR1 and total TFPR were assessed inflamed mucosa, observed in human IBD. In isolated PMN after fMLF stimulation, UFPR1 declined 70% ((fMLF)EC50 = 11 ± 1 nM; t1/2 = 15 s) and was stable for up to 4 h, whereas TFPR1 changed only slightly. Antagonists (tBoc-FLFLF, CsH) and metabolic inhibitor NaF prevented the fMLF-dependent UFPR1 decrease. Annexin A1 fragment Ac2-26 also induced decreases in UFPR1 ((Ac2-26)EC50 ∼ 3 µM). Proinflammatory agents (TNF-α, LPS), phosphatase inhibitor (okadaic acid), and G-protein activator (MST) modestly increased (fMLF)EC50, 2- to 4-fold, whereas PTX, Ca(2+) chelators (EGTA/BAPTA), H2O2, GM-CSF, ENA-78, IL-1RA, and LXA4 had no effect. Aggregation-inducing PAF, however, strongly inhibited fMLF-stimulated UFPR1 decreases. fMLF-driven PMN also demonstrated decreased UFPR1 after traversing monolayers of cultured intestinal epithelial cells, as did PMN in intestinal mucosal samples, demonstrating active inflammation from UC patients. Total TFPR remained high in PMN within inflamed crypts, migrating through crypt epithelium, and in the lamina propria-adjoining crypts, but UFPR1 was only observed at some peripheral sites on crypt aggregates. Loss of UFPR1 in PMN results from C-terminal S/T phosphorylation. Our results suggest G protein-insensitive, fMLF-dependent FPR1 phosphorylation in isolated suspension PMN, which may manifest in fMLF-driven transmigration and potentially, in actively inflamed tissues, except at minor discrete surface locations of PMN-containing crypt aggregates.
*Department of Pathology and Laboratory Medicine, Epithelial Pathobiology and Mucosal Inflammation Research Unit, Emory University School of Medicine, Atlanta, Georgia, USA; and Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Giovanna
G
Leoni
*Department of Pathology and Laboratory Medicine, Epithelial Pathobiology and Mucosal Inflammation Research Unit, Emory University School of Medicine, Atlanta, Georgia, USA; and Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Jeannie
J
Gripentrog
*Department of Pathology and Laboratory Medicine, Epithelial Pathobiology and Mucosal Inflammation Research Unit, Emory University School of Medicine, Atlanta, Georgia, USA; and Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Connie
C
Lord
*Department of Pathology and Laboratory Medicine, Epithelial Pathobiology and Mucosal Inflammation Research Unit, Emory University School of Medicine, Atlanta, Georgia, USA; and Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Marcia
M
Riesselman
*Department of Pathology and Laboratory Medicine, Epithelial Pathobiology and Mucosal Inflammation Research Unit, Emory University School of Medicine, Atlanta, Georgia, USA; and Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Ronen
R
Sumagin
*Department of Pathology and Laboratory Medicine, Epithelial Pathobiology and Mucosal Inflammation Research Unit, Emory University School of Medicine, Atlanta, Georgia, USA; and Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Charles A
CA
Parkos
*Department of Pathology and Laboratory Medicine, Epithelial Pathobiology and Mucosal Inflammation Research Unit, Emory University School of Medicine, Atlanta, Georgia, USA; and Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Asma
A
Nusrat
*Department of Pathology and Laboratory Medicine, Epithelial Pathobiology and Mucosal Inflammation Research Unit, Emory University School of Medicine, Atlanta, Georgia, USA; and Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA umbaj@montana.edu.
Algirdas J
AJ
Jesaitis
D002478:Cells, Cultured; D005455:Fluorescent Antibody Technique; D006801:Humans; D015151:Immunoblotting; D007249:Inflammation / Q000276:immunology* / Q000378:metabolism; D007413:Intestinal Mucosa / Q000276:immunology* / Q000378:metabolism; D018613:Microscopy, Confocal; D009504:Neutrophils / Q000276:immunology* / Q000378:metabolism; D010766:Phosphorylation; D044042:Receptors, Formyl Peptide / Q000378:metabolism*
D044042:Receptors, Formyl Peptide
FMLP; FPR1; fMLF; inflammation; inflammatory bowel disease